Q1 FY27: Revenue up 25%, PAT up 31%; Rs 32 interim dividend
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma Q1 FY27 consolidated revenue rose 25% YoY to Rs 1,626 cr; PAT grew 31% to Rs 334 cr. Adjusted EBITDA at Rs 454 cr, up 21%. India branded generics up 24%, Africa up 30%, US Generics up 57% to Rs 487 cr, Africa Institution up 83%. Asia declined 16%. Board declared first interim dividend of Rs 32 per share, totaling about Rs 400 cr. ROCE at 37%, RONW at 28%. Auditor issued unmodified review.
Strong all-around growth and healthy dividend payout signal robust momentum. Tax search matter from August 2025 remains pending with unascertainable impact.